Top Markets
Coin of the day
IMV Inc. IMV Inc.

IMV Inc.

IMV
Classifica tra le azioni #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Prezzo delle azioni
$0.82959892
Ultima sincronizzazione: 2023-05-23
Capitalizzazione di mercato
$4.16M
Variazione (1 giorno)
-0.04%
Variazione (1 anno)
0.00%
Paese
CA
Scambia IMV Inc. (IMV)

Categoria

Rapporto P/S per IMV Inc. (IMV)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di IMV Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per IMV Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE